

A class of carbonic anhydrase I – selective activators

Erol Licsandru, Muhammet Tanc, Istvan Kocsis, Mihail Barboiu & Claudiu T. Supuran

To cite this article: Erol Licsandru, Muhammet Tanc, Istvan Kocsis, Mihail Barboiu & Claudiu T. Supuran (2016): A class of carbonic anhydrase I – selective activators, Journal of Enzyme Inhibition and Medicinal Chemistry, DOI: [10.1080/14756366.2016.1232254](https://doi.org/10.1080/14756366.2016.1232254)

To link to this article: <http://dx.doi.org/10.1080/14756366.2016.1232254>



Published online: 01 Nov 2016.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

RESEARCH ARTICLE

A class of carbonic anhydrase I – selective activators

Erol Licsandru^a, Muhammet Tanc^b, Istvan Kocsis^a, Mihail Barboiu^a and Claudiu T. Supuran^b

^aAdaptive Supramolecular Nanosystems Group, Institut Européen des Membranes, University of Montpellier ENSCM-UMR CNRS 5635, Montpellier, France; ^bDepartment of Neurofarba and Laboratorio di Chimica Bioinorganica, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Sesto Fiorentino (Florence), Italy

ABSTRACT

A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.

ARTICLE HISTORY

Received 5 August 2016
Accepted 31 August 2016
Published online 24 October 2016

KEYWORDS

Anchoring to zinc-coordinated water; carbonic anhydrase; inhibition mechanism; inhibitors; occlusion of the active site entrance; out of the active site binding

Introduction





The carbonic anhydrases (CAs, EC 4.2.1.1) represent a superfamily of metalloenzymes, with six distinct genetic families known to date, the α -, β -, γ -, δ -, ζ -, and η -CAs, all of which efficiently catalyze the reaction between CO₂ and water, with the formation of bicarbonate and protons^{1–11}. The inhibition and the activation of CAs are well-understood processes: most types of classical inhibitors bind to the metal center within the enzyme active site^{12–21}, whereas the activators bind at the entrance of the active site cavity and participate in proton shuttling processes between the metal ion-bound water molecule and the environment^{22–24}. This leads to enhanced formation of the metal hydroxide, catalytically active species of the enzyme^{1,21–24}.


The substrates/reaction products involved in the CA catalyzed reaction, i.e. CO₂, bicarbonate and protons, are essential molecules/ions in many important physiologic processes in all life kingdoms (*Bacteria*, *Archaea*, and *Eukarya*), throughout the tree of life, and for this reason, relatively high amounts of these enzymes are present in different tissues/cell compartments of most investigated organisms^{1–11}.

Sulfonamides are the most important class of CA inhibitors (CAIs)^{25–43}, with at least 20 such compounds in clinical use for decades, or in clinical development^{44–79}. Sulfonamide/sulfamate CAIs are used as diuretics, antiglaucoma, anticonvulsant, and anti-obesity agents^{80–87}, whereas the anticancer and anti-infective use of such derivatives started to be investigated only recently^{3,4}. Furthermore, in the last period, the use of CAIs for the management of neuropathic pain⁸⁸, organ preservation without ischemia

reperfusion injury⁸⁹, and the management of cerebral ischemia⁹⁰ were also reported, extending thus the applications of these pharmacological agents. However, the activators of CAs (CAAs), although known for decades^{23,24}, do not have at this moment pharmacological applications. This is due to several reasons, the first of which has to do with the catalyzed reaction (Scheme 1).

As mentioned above, the catalytically effective species of all CAs has a metal hydroxide species within the active site, which for the α -CAs is a zinc hydroxide species generated from a water molecule bound to the Zn²⁺ ion (Equation (1) in Scheme 1). This is also the rate-determining step for the catalytic cycle of many CAs and it is assisted by buffers present in the medium as well as by an amino acid residue from the middle of the active site cavity, His64, which has a pK_a of about 7 and may shuttle protons between the active site and the environment^{23,24}. The second step (Equation (2) in Scheme 1) involves the nucleophilic attack of the zinc hydroxide to the CO₂ molecule bound in a hydrophobic pocket, with formation of bicarbonate coordinated to zinc, which is thereafter replaced by an incoming water molecule, with formation of the acidic species of the enzyme, with water as the fourth zinc ligand^{1–3,23,24}. Many CAs are highly effective catalysts, with turnover numbers of $>10^8$ s⁻¹, close to the limit of diffusion-controlled processes^{1–3}. Thus, many researchers in the period starting with 50s until the 90s were reluctant to admit that CAs may have activators. Only in 1997, we reported the first X-ray crystal structure of an activator bound to the human (h) CA isoform hCA II. This activator was histamine²³. The activator was found bound at the entrance of the CA active site cavity, with the imidazole

CONTACT Mihail Barboiu  mihail-dumitru.barboiu@univ-montp2.fr  Adaptive Supramolecular Nanosystems Group, Institut Européen des Membranes, University of Montpellier ENSCM-UMR CNRS 5635, Place Eugene Bataillon CC047, Montpellier, F-34095, France; Claudiu T. Supuran  claudiu.supuran@unifi.it  Department of Neurofarba and Laboratorio di Chimica Bioinorganica, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Sesto Fiorentino (Florence), Italy



Scheme 1. CA-catalyzed CO₂ hydration reactions (steps 1 and 2), and CA activation with an activator molecule A.

moiety participating in shuttling protons between the active site and the bulk solvent, thus acting as a second proton shuttle of the enzyme in addition to His64, whereas the amino group from the aminoethyl moiety of histamine did not participate in any interaction with the enzyme active site²³.

The second reason why CAAs do not have for the moment pharmacological applications is due to their difficult pharmacology. Indeed, it has been reported that some CAAs (such as phenylalanine or imidazole) administered to experimental animals may produce an important pharmacological enhancement of synaptic efficacy, spatial learning, and memory, proving that this class of relatively unexplored enzyme modulators may have important applications in conditions in which learning and memory are impaired, such as for example aging or Alzheimer's disease^{91,92}. One must also mention that it was reported that the levels of CA are significantly diminished in the brain of patients affected by Alzheimer's disease⁹³ and these facts strongly support the involvement of different brain CA isozymes in cognitive functions. However, no clinical trials for the use of CAAs for the management of these conditions were done at this moment. One should mention that the chemistry and biochemistry of this class of derivatives was thoroughly investigated, with a large number of activators classes (mainly histamine, catecholamine, and amino acid derivatives^{94–104}) reported and several CA – activator adducts X-ray crystal structures available^{23,24,95–97}. However, few isoform-selective CAAs are known to date. Here we report a class of CA I-selective CAAs, based on the histamine scaffold, which has been derivatized by using cyanate/dicyanate chemistry.

Materials and methods

Chemistry

All the compounds were synthesized following the general procedure described below. The amine (30 mmol) was mixed with the corresponding amount of isocyanate, under sonication (1 eq.: 1eq. for the monourea compounds and 2 eq. for the diurea compounds). The mixture was solubilized in 10 ml of tetrahydrofuran (THF), 5 ml of ethylacetate, and 10 ml of dimethylacetamide. The reaction mixture was heated to 120 °C for 15 min. When the precipitation began, 5 ml of acetonitrile were added and the heating was maintained for another hour. The resulting product (a white powder) was filtered and washed with methanol. The exceptions of the protocol were compounds **1**, **6**, **10**, and **11** for which the reaction temperature was 60 °C and compounds **2**, **7**, **12**, and **13** for which the reaction temperature was 80 °C. Compound **1** is soluble in the reaction mixture and, therefore, the purification procedure consisted in evaporation of the solvent under vacuum in a round bottomed flask and recrystallization from CHCl₃. Alternatively a microwave reactor has been used. The procedure was the following: the isocyanate was dissolved in 5 ml of acetonitrile and added over the amine in the microwave reactor. The reaction was performed at 140 °C under energetic stirring, for 15 min. The product was filtered and washed with methanol. In the case of compounds **1**, **6**, **10**, and **11**, the temperature was

50 °C and for compounds **2**, **7**, **12**, and **13** was 90 °C. For compound **1**, the purification method was the same. Ureas **1–22** were characterized using ¹H NMR methods and mass spectrometry.

1-(2-(1H-imidazol-4-yl)ethyl)-3-butylurea **1**: (mass spectrometry, ES M⁺⁺ = 211.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.86 (t, 3H, CH₃CH₂); 1.30 (m, 4H, CH₃CH₂CH₂CH₂); 2.58 (t, 2H, NHCH₂CH₂); 2.96 (q, 2H, CH₂CH₂NH); 3.21 (q, 2H, CH₂CH₂NH); 5.75 (s mod, 1H, NHCH₂); 5.83 (s mod, 1H, NHCH₂); 6.78 (s, 1H, C CHNH imidazole); 7.55 (s, 1H, N CHNH imidazole).

1-(2-(1H-imidazol-4-yl)ethyl)-3-hexylurea **2**: (mass spectrometry, ES M⁺⁺ = 239.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.86 (t, 3H, CH₃CH₂); 1.24–1.34 (m, 8H, CH₃(CH₂)₄CH₂); 2.57 (t, 2H, NHCH₂CH₂); 2.96 (q, 2H, CH₂CH₂NH); 3.21 (q, 2H, CH₂CH₂NH); 5.75 (s mod, 1H, NHCH₂); 5.84 (s mod, 1H, NHCH₂); 6.75 (s, 1H, C CHNH imidazole); 7.54 (s, 1H, N CHNH imidazole).

1-(2-(1H-imidazol-4-yl)ethyl)-3-octylurea **3**: (mass spectrometry, ES M⁺⁺ = 267.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.86 (t, 3H, CH₃CH₂); 1.25–1.34 (m, 12H, CH₃(CH₂)₆CH₂); 2.58 (t, 2H, NHCH₂CH₂); 2.95 (q, 2H, CH₂CH₂NH); 3.21 (q, 2H, CH₂CH₂NH); 5.74 (s mod, 1H, NHCH₂); 5.82 (s mod, 1H, NHCH₂); 6.76 (s, 1H, C CHNH imidazole); 7.52 (s, 1H, N CHNH imidazole).

1-(2-(1H-imidazol-4-yl)ethyl)-3-dodecylurea **4**: (mass spectrometry, ES M⁺⁺ = 323.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.85 (t, 3H, CH₃CH₂); 1.25–1.33 (m, 20H, CH₃(CH₂)₁₀CH₂); 2.57 (t, 2H, NHCH₂CH₂); 2.93 (q, 2H, CH₂CH₂NH); 3.21 (q, 2H, CH₂CH₂NH); 5.75 (s mod, 1H, NHCH₂); 5.83 (s mod, 1H, NHCH₂); 6.75 (s, 1H, C CHNH imidazole); 7.50 (s, 1H, N CHNH imidazole).

1-(2-(1H-imidazol-4-yl)ethyl)-3-octadecylurea **5**: (mass spectrometry, ES M⁺⁺ = 407.3)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.86 (t, 3H, CH₃CH₂); 1.24–1.33 (m, 32H, CH₃(CH₂)₁₆CH₂); 2.58 (t, 2H, NHCH₂CH₂); 2.95 (q, 2H, CH₂CH₂NH); 3.21 (q, 2H, CH₂CH₂NH); 5.75 (s mod, 1H, NHCH₂); 5.82 (s mod, 1H, NHCH₂); 6.78 (s, 1H, C CHNH imidazole); 7.56 (s, 1H, N CHNH imidazole).

1-(Butane-1,4-diyl)bis(3-(2-(2H-imidazol-4-yl)ethyl)urea) **6**: (mass spectrometry, ES M⁺⁺ = 363.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.32 (m, 4H, CH₃(CH₂)₂CH₂); 2.58 (t, 4H, NHCH₂CH₂); 2.95 (q, 4H, CH₂CH₂NH);

3.22 (q, 4H, CH₂CH₂NH), 5.78 (s mod, 2H, NHCH₂); 5.88 (s mod, 2H, NHCH₂); 6.76 (s, 2H, C CHNH imidazole); 7.51 (s, 2H, N CHNH imidazole).

1-(Hexane-1,6-diyl)bis(3-(2-(2H-imidazol-4-yl)ethyl)urea) 7: (mass spectrometry, ES M⁺ = 391.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.22–1.36 (m, 8H, CH₃(CH₂)₄CH₂); 2.57 (t, 4H, NHCH₂CH₂); 2.92 (q, 4H, CH₂CH₂NH); 3.22 (q, 4H, CH₂CH₂NH); 5.76 (s mod, 2H, NHCH₂); 5.85 (s mod, 2H, NHCH₂); 6.76 (s, 2H, C CHNH imidazole); 7.55 (s, 2H, N CHNH imidazole).

1-(Octane-1,8-diyl)bis(3-(2-(2H-imidazol-4-yl)ethyl)urea) 8: (mass spectrometry, ES M⁺ = 419.3)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.24–1.36 (m, 12H, CH₃(CH₂)₆CH₂); 2.58 (t, 4H, NHCH₂CH₂); 2.95 (q, 4H, CH₂CH₂NH); 3.21 (q, 4H, CH₂CH₂NH); 5.76 (s mod, 2H, NHCH₂); 5.84 (s mod, 2H, NHCH₂); 6.77 (s, 2H, C CHNH imidazole); 7.54 (s, 2H, N CHNH imidazole).

1-(Dodecane-1,12-diyl)bis(3-(2-(2H-imidazol-4-yl)ethyl)urea) 9: (mass spectrometry, ES M⁺ = 475.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.24–1.33 (m, 16H, CH₃(CH₂)₈CH₂); 2.59 (t, 4H, NHCH₂CH₂); 2.95 (q, 4H, CH₂CH₂NH); 3.22 (q, 4H, CH₂CH₂NH); 5.77 (s mod, 2H, NHCH₂); 5.83 (s mod, 2H, NHCH₂); 6.82 (s, 2H, C CHNH imidazole); 7.62 (s, 2H, N CHNH imidazole).

(R)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(3-methylbutan-2-yl)urea 10: (mass spectrometry, ES M⁺ = 225.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.81 (q, 6H, CH₃CHCH₃); 0.92 (d, 3H, CH₃CHHC₂); 1.57 (h, 1H, CH₃CHCH₃); 2.60 (t, 2H, NHCH₂CH₂); 3.21 (q, 2H, CH₂CH₂NH); 3.45 (m, 1H, CH₂CH₃CHNH); 5.68 (s mod, 1H, NHCH₂); 5.71 (s mod, 1H, NHCH₂); 6.82 (s, 1H, C CHNH imidazole); 7.51 (s, 1H, N CHNH imidazole).

(S)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(3-methylbutan-2-yl)urea 11: (mass spectrometry, ES M⁺ = 225.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.81 (q, 6H, CH₃CHCH₃); 0.92 (d, 3H, CH₃CHHC₂); 1.56 (h, 1H, CH₃CHCH₃); 2.57 (t, 2H, NHCH₂CH₂); 3.20 (q, 2H, CH₂CH₂NH); 3.45 (m, 1H, CH₂CH₃CHNH); 5.68 (s mod, 1H, NHCH₂); 5.70 (s mod, 1H, NHCH₂); 6.76 (s, 1H, C CHNH imidazole); 7.51 (s, 1H, N CHNH imidazole).

(R)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(hexan-2-yl)urea 12: (mass spectrometry, ES M⁺ = 239.3)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.86 (t, 3H, CH₃CH₂); 0.97 (d, 3H, CH₃CHHC₂); 1.24 (m, 6H, CH₃(CH₂)₃CH₂); 2.57 (t, 2H, NHCH₂CH₂); 3.21 (q, 2H, CH₂CH₂NH); 3.54 (m, 1H, CH₂CH₃CHNH); 5.64 (s mod, 1H, NHCH₂); 5.69 (s mod, 1H, NHCH₂); 6.81 (s, 1H, C CHNH imidazole); 7.51 (s, 1H, N CHNH imidazole).

(S)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(hexan-2-yl)urea 13: (mass spectrometry, ES M⁺ = 239.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.84 (t, 3H, CH₃CH₂); 0.97 (d, 3H, CH₃CHHC₂); 1.23 (m, 6H, CH₃(CH₂)₃CH₂); 2.56 (t, 2H,

NHCH₂CH₂); 3.20 (q, 2H, CH₂CH₂NH); 3.54 (m, 1H, CH₂CH₃CHNH); 5.63 (s mod, 1H, NHCH₂); 5.70 (s mod, 1H, NHCH₂); 6.80 (s, 1H, C CHNH imidazole); 7.50 (s, 1H, N CHNH imidazole).

(R)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(octan-2-yl)urea 14: (mass spectrometry, ES M⁺ = 267.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.85 (t, 3H, CH₃CH₂); 0.97 (d, 3H, CH₃CHHC₂); 1.24 (m, 10H, CH₃(CH₂)₅CH₂); 2.57 (t, 2H, NHCH₂CH₂); 3.20 (q, 2H, CH₂CH₂NH); 3.53 (m, 1H, CH₂CH₃CHNH); 5.67 (s mod, 1H, NHCH₂); 5.69 (s mod, 1H, NHCH₂); 6.82 (s, 1H, C CHNH imidazole); 7.51 (s, 1H, N CHNH imidazole).

(S)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(octan-2-yl)urea 15: (mass spectrometry, ES M⁺ = 267.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 0.85 (t, 3H, CH₃CH₂); 0.97 (d, 3H, CH₃CHHC₂); 1.23 (m, 10H, CH₃(CH₂)₅CH₂); 2.57 (t, 2H, NHCH₂CH₂); 3.20 (q, 2H, CH₂CH₂NH); 3.49 (m, 1H, CH₂CH₃CHNH); 5.66 (s mod, 1H, NHCH₂); 5.69 (s mod, 1H, NHCH₂); 6.75 (s, 1H, C CHNH imidazole); 7.51 (s, 1H, N CHNH imidazole).

1,1'-((1*r*,4*r*)-cyclohexane-1,4-diyl)bis(3-(2-(1H-imidazol-4-yl)ethyl)urea) 16: (mass spectrometry, ES M⁺ = 389.3)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.09 (t mod, 5H, CHCH₂CH₂); 1.09 (dd mod, 5H, CHCH₂CH₂); 2.58 (t, 4H, NHCH₂CH₂); 3.32 (q, 4H, CH₂CH₂NH); 5.69 (s mod, 2H, NHCH₂); 5.74 (s mod, 2H, NHCH₂); 6.68 (s, 2H, C CHNH imidazole); 7.56 (s, 2H, N CHNH imidazole).

1-(2-(1H-imidazol-4-yl)ethyl)-3-phenylurea 17: (mass spectrometry, ES M⁺ = 231.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 2.66 (t, 2H, NHCH₂CH₂); 2.58 (t, 2H, NHCH₂CH₂); 3.31 (q, 2H, CH₂CH₂NH); 6.18 (s mod, 1H, C CHNH imidazole); 6.87 (t, 1H, p-CH Ph); 7.20 (t, 2H, m-CH Ph); 7.375 (d, 2H, o-CH Ph); 7.55 (s, 1H, N CHNH imidazole); 8.48 (s, 1H, CHNH imidazole).

1,1'-(2,2'-(1,3-phenylene)bis(propane-2,2-diyl))bis(3-(2-(1H-imidazol-4-yl)ethyl)urea) 18: (mass spectrometry, ES M⁺ = 467.2)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.61 (s, 12H, CH₃); 2.08 (s, 2H, CH); 2.56 (t, 4H, NHCH₂CH₂); 3.17 (q, 4H, CH₂CH₂NH); 5.80 (s mod, 2H, NHCH₂); 6.24 (s, 1H, C CC phenyl); 6.75 (s, 2H, C CHNH imidazole); 7.13–7.18 (m, 3H, CCHCH phenyl and s mod, 2H, NHCH₂); 7.33 (s mod, 2H, CHCHCH phenyl); 7.52 (s, 1H, N CHNH imidazole).

(R)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(1-phenylethyl)urea 19: (mass spectrometry, ES M⁺ = 259.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.29 (d, 3H, CH₃); 2.57 (t, 2H, NHCH₂CH₂); 3.21 (q, 2H, CH₂CH₂NH); 4.70 (qv, 1H, CH₃CHNH); 5.79 (s mod, 1H, NHCH₂); 6.37 (d mod, 1H, NH-CH-Ph); 6.77 (s, 1H, C CHNH imidazole); 7.17–7.33 (m, 5H, phenyl); 7.56 (s, 1H, N CHNH imidazole).

(S)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(1-phenylethyl)urea 20: (mass spectrometry, ES M⁺ = 259.1)

¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm) = 1.29 (d, 3H, CH₃); 2.60 (t, 2H, NHCH₂CH₂); 3.19 (q, 2H, CH₂CH₂NH); 4.72 (qv, 1H, CH₃CHNH);

5.79 (s mod, 1H, *NHCH*2); 6.37 (d mod, 1H, *NH-CH-Ph*); 6.80 (s, 1H, C *CHNH* imidazole); 7.19–7.33 (m, 5H, phenyl); 7.61 (s, 1H, N *CHNH* imidazole).

(R)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(1-(4-fluorophenyl)ethyl)urea 21:
(mass spectrometry, ES $M^{*+} = 277.1$)

$^1\text{H-NMR}$ (DMSO- d_6 , 300 MHz) δ (ppm) = 1.28 (d, 3H, CH₃); 2.58 (t, 2H, *NHCH*2CH₂); 3.20 (q, 2H, CH₂CH₂NH); 4.78 (qv, 1H, CH₃CHNH); 5.80 (s mod, 1H, *NHCH*2); 6.40 (d mod, 1H, *NH-CH-Ph*); 6.80 (s, 1H, C *CHNH* imidazole); 7.13–7.18 (m, 2H, CHCCH phenyl); 7.27–7.32 (m, 2H, CHCFCCH phenyl); 7.52 (s, 1H, N *CHNH* imidazole).

(S)-1-(2-(1H-imidazol-4-yl)ethyl)-3-(1-(4-fluorophenyl)ethyl)urea 22:
(mass spectrometry, ES $M^{*+} = 277.1$)

$^1\text{H-NMR}$ (DMSO- d_6 , 300 MHz) δ (ppm) = 1.28 (d, 3H, CH₃); 2.58 (t, 2H, *NHCH*2CH₂); 3.22 (q, 2H, CH₂CH₂NH); 4.72 (qv, 1H, CH₃CHNH); 5.79 (s mod, 1H, *NHCH*2); 6.39 (d mod, 1H, *NH-CH-Ph*); 6.79 (s, 1H, C *CHNH* imidazole); 7.09–7.15 (m, 2H, CHCCH phenyl); 7.27–7.31 (m, 2H, CHCFCCH phenyl); 7.58 (s, 1H, N *CHNH* imidazole).

Carbonic anhydrase assay

A stopped-flow method¹⁰⁵ has been used for assaying the CA catalyzed CO₂ hydration activity with Phenol red as indicator, working at the absorbance maximum of 557 nm, following the initial rates of the CA-catalyzed CO₂ hydration reaction for 10–100 s. For each activator, at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of activator (0.1 mM) were prepared in distilled-deionized water with 5% DMSO and dilutions up to 0.1 nM were done thereafter with distilled-deionized water. The activation constant (K_A), defined similarly with the inhibition constant K_i , was obtained by considering the classical Michaelis–Menten equation (Equation (4)), which has been fitted by non-linear least squares by using PRISM 3:

$$v = v_{\max} / \{1 + K_M/[S] (1 + [A]_f/K_A)\} \quad (4)$$

where $[A]_f$ is the free concentration of activator.

Working at substrate concentrations considerably lower than K_M ($[S] \ll K_M$), and considering that $[A]_f$ can be represented in the form of the total concentration of the enzyme ($[E]_t$) and activator ($[A]_t$), the obtained competitive steady-state equation for determining the activation constant is given by the following equation^{23,24,95–104}:

$$v = v_0 \cdot K_A / \{K_A + ([A]_t - 0.5\{([A]_t + [E]_t + K_A) - ([A]_t + [E]_t + K_A)^2 - 4[A]_t \cdot [E]_t\}^{1/2})\} \quad (5)$$

where v_0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator. All CA isozymes used in the

experiments were purified recombinant proteins obtained as reported earlier by our group^{23,24}.

Results and discussion

Chemistry


The rationale for designing new CAAs reported in this paper is based on the reported X-ray crystal structure for the hCA II – histamine adduct²³. As mentioned above, the aminoethyl moiety of the activator does not make relevant contacts with the enzyme and is free to be derivatized as it points out towards the exit of the active site. In this way, the imidazole moiety of the activator can participate to the proton shuttling processes crucial for enhancing the catalytic efficiency of the enzyme, whereas the derivatized amino group may lead to a further stabilization of the enzyme-activator adduct. In an earlier work¹⁰⁶, we showed that sulfonamido, carboxamido, and ureido/thioureido derivatives of histamine (at the aliphatic portion of the molecule) act as efficient activators of several CA isoforms, such as hCA I, hCA II, and bCA IV (b = bovine isoform). As only a few (more exactly 5) ureido derivatives of histamine were reported, all of them incorporating aromatic R moieties, here we decided to investigate a larger such series of ureas and diureas, obtained by reacting histamine with alkyl/aryl isocyanates and di-isocyanates, as describes in Scheme 2.

A rather large number of such derivatives were obtained (Table 1), which incorporate various alkyl moieties of variable length, cycloalkyl, and aryl moieties. All compounds were thoroughly characterized by physico-chemical procedures which confirmed their structure (see Materials and methods for details).

CA activation



















Ureas **1–22** and histamine were assayed for the activation of the physiologically most important cytosolic isoforms hCA I and II (Table 1). It should be mentioned that these are widespread isoforms in many tissues (e.g. red blood cells contain approximately 150 μM of hCA I and 20 μM of hCA II)¹, including not only the blood but also the gastro-intestinal tract, kidneys, lungs, and the brain^{1,7}.

Data of Table 1 show some very interesting structure-activity relationship (SAR) data for the activation of these two isoforms with histamine and its ureido/bisureido derivatives **1–22**. The most salient feature is that unlike histamine, which is a poor hCA II activator (K_A of 125 μM) but a rather efficient hCA I activator (K_A of 2.0 μM), the ureas **1–22** do not activate at all hCA II, but are all of them effective hCA I activators, with K_A s in the range of 0.73–3.4 μM (Table 1). The second rather interesting feature of this class of CAAs is the fact that the activation constants against hCA I show a rather modest range, with a minimal variation of potency, irrespective of the rather diverse substitution pattern at the ureido moiety, or whether they are mono- or bis-urea derivatives (and as a consequence they contain one or two imidazole moieties able to participate in proton shuttling processes). Thus, the most



Scheme 2. Synthesis of ureas **1–22** from histamine and isocyanates/diisocyanates.

Table 1. CA activation against isoforms hCA I and II with ureas 1–22 and histamine as standard, by a stopped-flow CO₂ hydrase assay¹⁰⁵. K_A=activation constant.

No.	Structure	K _A hCA I (μM)*	K _A hCA II (μM)*
1		3.1	>200
2		2.7	>200
3		3.0	>200
4		3.4	>200
5		2.8	>200
6		2.9	>200
7		3.1	>200
8		2.2	>200
9		1.7	>200
10		1.6	>200
11		1.5	>200
12		3.0	>200
13		2.2	>200
14		3.1	>200
15		3.0	>200
16		1.6	>200
17		1.1	>200
18		0.73	>200

(continued)

Table 1. Continued

No.	Structure	K_A hCA I (μ M)*	K_A hCA II (μ M)*
19		1.2	>200
20		1.4	>200
21		0.98	>200
22		0.97	>200
–	Histamine	2.0	125

*Errors in the range of $\pm 10\%$ of the reported values, from three different determinations (data not shown).

effective activator is indeed a *bis*-urea (compound **18**), which contains two imidazoles in its molecule and showed a K_A of $0.73 \mu\text{M}$, being thus 2.74 times a more effective hCA I activator compared to histamine. However, the other submicromolar CAAs detected here, compounds **21** and **22** (K_A s of 0.97 – $0.98 \mu\text{M}$) were monoureas, containing only one imidazole moiety. Several of the ureas investigated here (e.g. **1–8** and **12–15**) were slightly less effective hCA I activators compared with histamine, with K_A s in the range of 2.2 – $3.4 \mu\text{M}$. It is difficult to explain this loss of activity, also considering the fact that some aryl-ureido histamines reported earlier¹⁰⁶, possessing a very diverse substitution pattern compared with these compounds, possessed a much more efficient activating profile against hCA I (and also activated hCA II and bCA IV). Probably the rather long aliphatic moieties present in the ureas investigated here were detrimental for the binding of the activator at the entrance of the active site cavity, a region of the enzyme rich in hydrophilic amino acid residues^{1,18}. However, although slightly less effective than histamine, these compounds did show activating properties against this isoform, but not at all against hCA II, which is probably even more difficult to explain. However, as explained earlier by us²³, the entrance of the active site cavity of the two isoforms are very diverse, with hCA II possessing a cluster of at least 6 histidine residues (His3, 4, 10, 15, 17, and 64) which is absent in hCA I. The much more hydrophilic environment at the entrance of hCA II active site probably explains why the hydrophobic ureas reported here **1–22** do not efficiently bind to this enzyme, and do not show any CA activating effect. This is, as far as we know, the only example of isoform-selective CAA, and may be of relevance for better understanding the physiology/pharmacology of hCA I.

Conclusions

By catalyzing the simple but highly important hydration of carbon dioxide to bicarbonate and protons, CAs are involved in critical

steps of the life cycle of many organisms, including eukaryotes, *Bacteria* and *Archaea*. A large number of CA inhibitors have pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, whereas activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease, conditions in which a diminished CA activity was reported. We report here a series of ureido/*bis*-ureido histamine derivatives which were investigated for their activating effects against the cytosolic human (h) isoform hCA I and II. We observed that all these compounds, unlike histamine or other activator classes, show no activating effects on the widespread, physiologically dominant isoform hCA II, but were rather effective hCA I activators. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform.

Disclosure statement

One author (C. T. S.) declares conflict of interest, being author of several patents in the field of CA inhibitors/activators. This research was financed by several EU projects (Euroxy, Metoxia, DeZnIt, and Dynano). The other authors do not declare conflict of interest.

References

- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81.
- Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011;10:767–77.

3. Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? *J Enzyme Inhib Med Chem* 2015;30:325–32.
4. Supuran CT, Capasso C. The η -class carbonic anhydrases as drug targets for antimalarial agents. *Expert Opin Ther Targets* 2015;19:551–63.
5. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2012;27:759–72.
6. Supuran CT. Carbonic anhydrase inhibitors. *Bioorg Med Chem Lett* 2010;20:3467–74.
7. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. *J Enzyme Inhib Med Chem* 2004;19:199–229.
8. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. *Future Med Chem* 2011;3:1165–80.
9. Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? *Front Pharmacol* 2011;2:34.
10. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. *Med Res Rev* 2003;23:146–89.
11. Luca C, Barboiu M, Supuran CT. Stability constant of complex inhibitors and their mechanism of action. *Rev Roum Chim* 1991;36:1169–73.
12. De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. *J Inorg Biochem* 2012;111:117–29.
13. Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of recombinant beta-carbonic anhydrase (PgiCAB) identified in the genome of the oral pathogenic bacterium *Porphyromonas gingivalis*. *J Enzyme Inhib Med Chem* 2015;30:366–70.
14. Supuran CT. Carbonic anhydrase inhibitors: an editorial. *Expert Opin Ther Pat* 2013;23:677–9.
15. Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO₂ capture. *J Enzyme Inhib Med Chem* 2013;28:229–30.
16. Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. *Expert Opin Ther Pat* 2013;23:693–704.
17. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs – antimetabolites acting as carbonic anhydrase, dihydropterolate synthase and dihydrofolate reductase inhibitors. *J Enzyme Inhib Med Chem* 2014;29:379–87.
18. Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32.
19. Barboiu M, Supuran CT, Menabuoni L, et al. Carbonic anhydrase inhibitors, synthesis of topically effective intraocular pressure lowering agents derived from 5-(aminoalkylcarboxamido)-1,3,4-thiadiazole-2-sulfonamide. *J Enzyme Inhib* 1999;15:23–46.
20. Zimmerman S, Innocenti A, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of the prokaryotic beta and gamma-class enzymes from *Archaea* with sulfonamides. *Bioorg Med Chem Lett* 2004;14:6001–6.
21. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68.
22. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II – trithiocarbonate adduct – an inhibitor mimicking the sulfonamide and urea binding to the enzyme. *Bioorg Med Chem Lett* 2010;20:474–8.
23. Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. *Biochemistry* 1997;36:10384–92.
24. Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton transfer processes within the active site of an enzyme. *Chemistry* 2006;12:7057–66.
25. Vullo D, De Luca V, Del Prete S, et al. Sulfonamide inhibition studies of the γ -carbonic anhydrase from the Antarctic cyanobacterium *Nostoc commune*. *Bioorg Med Chem* 2015;23:1728–34.
26. Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO₂-sensing carbonic anhydrase Can2 from the pathogenic fungus *Cryptococcus neoformans*. *J Mol Biol* 2009;385:1207–20.
27. Pacchiano F, Carta F, Vullo D, et al. Inhibition of β -carbonic anhydrases with ureido-substituted benzenesulfonamides. *Bioorg Med Chem Lett* 2010;20:102–5.
28. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. *J Med Chem* 2012;55:1721–30.
29. Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from *Cryptococcus neoformans*, *Candida albicans* and *Candida glabrata*. *Bioorg Med Chem Lett* 2012;22:859–62.
30. Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from *Mycobacterium tuberculosis*. *J Enzyme Inhib Med Chem* 2013;28:407–11.
31. Carta F, Innocenti A, Hall RA, et al. Carbonic anhydrase inhibitors. Inhibition of the β -class enzymes from the fungal pathogens *Candida albicans* and *Cryptococcus neoformans* with branched aliphatic-/aromatic carboxylates and their derivatives. *Bioorg Med Chem Lett* 2011;21:2521–6.
32. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from *Helicobacter pylori* as novel drug targets. *Curr Pharm Des* 2008;14:622–30.
33. Minakuchi T, Nishimori I, Vullo D, et al. Molecular cloning, characterization and inhibition studies of the Rv1284 β -carbonic anhydrase from *Mycobacterium tuberculosis* with sulfonamides and a sulfamate. *J Med Chem* 2009;52:2226–32.
34. Nishimori I, Minakuchi T, Vullo D, et al. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of a new β -carbonic anhydrase from *Mycobacterium tuberculosis*. *J Med Chem* 2009;52:3116–20.
35. Güzel Ö, Maresca A, Scozzafava A, et al. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. *J Med Chem* 2009;52:4063–7.
36. Carta F, Maresca A, Suarez Covarrubias A, et al. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β -carbonic anhydrase from *Mycobacterium tuberculosis*, Rv3588c. *Bioorg Med Chem Lett* 2009;19:6649–54.
37. Nishimori I, Minakuchi T, Maresca A, et al. The β -carbonic anhydrases from *Mycobacterium tuberculosis* as drug targets. *Curr Pharm Des* 2010;16:3300–9.

38. Winum JY, Kohler S, Supuran CT. *Brucella* carbonic anhydrases: new targets for designing anti-infective agents. *Curr Pharm Des* 2010;16:3310–16.
39. Vullo D, Nishimori I, Minakuchi T, et al. Inhibition studies with anions and small molecules of two novel β -carbonic anhydrases from the bacterial pathogen *Salmonella enterica* serovar Typhimurium. *Bioorg Med Chem Lett* 2011;21:3591–5.
40. Maresca A, Vullo D, Scozzafava A, Supuran CT. Inhibition of the α - and β -carbonic anhydrases from the gastric pathogen *Helicobacter pylori* with anions. *J Enzyme Inhib Med Chem* 2013;28:388–91.
41. Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the β -class carbonic anhydrases from *Mycobacterium tuberculosis* with carboxylic acids. *J Enzyme Inhib Med Chem* 2013;28:392–6.
42. Vullo D, Nishimori I, Scozzafava A, et al. Inhibition studies of a β -carbonic anhydrase from *Brucella suis* with a series of water soluble glycosylsulfanilamides. *Bioorg Med Chem Lett* 2010;20:2178–82.
43. Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors. The β -carbonic anhydrase from *Helicobacter pylori* is a new target for sulfonamide and sulfamate inhibitors. *Bioorg Med Chem Lett* 2007;17:3585–94.
44. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: new pharmacological opportunities due to related binding site recognition. *J Med Chem* 2004;47:550–7.
45. Di Fiore A, Pedone C, D'Ambrosio K, et al. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related, cyclooxygenase II “selective” inhibitor celecoxib. *Bioorg Med Chem Lett* 2006;16:437–42.
46. Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. *Angew Chem Int Ed Engl* 2007;46:7697–9.
47. Casini A, Scozzafava A, Mincione F, et al. Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. *J Med Chem* 2000;43:4884–92.
48. Scozzafava A, Menabuoni L, Mincione F, Supuran CT. Carbonic anhydrase inhibitors. A general approach for the preparation of water solublesulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long lasting, topical intraocular pressure lowering properties. *J Med Chem* 2002;45:1466–76.
49. Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. *J Enzyme Inhib Med Chem* 2012;27:138–47.
50. Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. *J Enzyme Inhib Med Chem* 2009;24:1–39.
51. Švastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. *FEBS Lett* 2004;577:439–45.
52. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. *Radiother Oncol* 2009;92:423–8.
53. Ahlskog KJ, Dumelin CE, Trüssel S, et al. *In vivo* targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. *Bioorg Med Chem Lett* 2009;19:4851–6.
54. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. *J Med Chem* 2011;54:1896–902.
55. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. *Curr Top Med Chem* 2007;7:849–54.
56. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. *Expert Opin Ther Pat* 2012;22:79–88.
57. Steele RM, Batugo MR, Benedini F, et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. *Bioorg Med Chem Lett* 2009;19:6565–70.
58. Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. *Bioorg Med Chem Lett* 2011;21:3216–21.
59. Alterio V, Vitale RM, Monti SM, et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. *J Am Chem Soc* 2006;128:8329–35.
60. Alterio V, De Simone G, Monti SM, et al. Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides – solution and crystallographic studies. *Bioorg Med Chem Lett* 2007;17:4201–7.
61. Wagner J, Avvaru BS, Robbins AH, et al. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. *Bioorg Med Chem* 2010;18:4873–8.
62. Biswas S, Aggarwal M, Guzel O, et al. Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. *Bioorg Med Chem* 2011;19:3732–8.
63. Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. *Chem Commun (Camb)* 2010;46:8371–3.
64. Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. *Bioorg Med Chem* 2011;19:3105–19.
65. Hen N, Bialer M, Yagen B, et al. Anticonvulsant 4-amino-benzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII and XIV. *J Med Chem* 2011;54:3977–81.
66. Kolayli S, Karahalil F, Sahin H, et al. Characterization and inhibition studies of an α -carbonic anhydrase from the endangered sturgeon species *Acipenser gueldenstaedti*. *J Enzyme Inhib Med Chem* 2011;26:895–900.
67. Güzel Ö, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Phenacetyl-, pyridylacetyl- and thienylacetyl-substituted aromatic sulfonamides act as potent and

- selective isoform VII inhibitors. *Bioorg Med Chem Lett* 2009;19:3170–3.
68. Güzel Ö, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl-, pyridylacetyl- and thienylacetyl-tails act as potent inhibitors of human mitochondrial isoforms VA and VB. *Bioorg Med Chem* 2009;17:4894–9.
 69. Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Arylsulfonylureido and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. *J Enzyme Inhib* 1999;14:343–63.
 70. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating 1,2,4-triazine moieties. *Bioorg Med Chem Lett* 2004;14:5427–33.
 71. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors. Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX. *Bioorg Med Chem Lett* 2005;15:3102–8.
 72. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. *Oncotarget* 2012;3:84–97.
 73. Carta F, Scozzafava A, Supuran CT. Sulfonamides (RSO_2NH_2): a patent review 2008–2012. *Expert Opin Ther Pat* 2012;22:747–58.
 74. Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. *Expert Opin Ther Pat* 2013;23:705–16.
 75. Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). *Expert Opin Ther Pat* 2013;23:737–49.
 76. Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). *Expert Opin Ther Pat* 2013;23:681–91.
 77. Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. *Expert Opin Emerg Drugs* 2012;17:11–15.
 78. Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. *Expert Opin Ther Pat* 2013;23:725–35.
 79. Supuran CT. The safety and clinical efficacy of acetazolamide for the treatment of idiopathic intracranial hypertension. *Expert Rev Neurother* 2015;15:851–6.
 80. De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2013;8:793–810.
 81. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? *J Med Chem* 1999;42:2641–50.
 82. Borrás J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors. Part 73. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? *Bioorg Med Chem* 1999;7:2397–406.
 83. Supuran CT. Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. *Mol Divers* 2011;15:305–16.
 84. Karioti A, Ceruso M, Carta F, et al. New natural product carbonic anhydrase inhibitors incorporating phenol moieties. *Bioorg Med Chem* 2015;23:7219–25.
 85. Winum JY, Supuran CT. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2015;30:321–4.
 86. Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. *Eur J Med Chem* 1996;31:1001–10.
 87. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. *Bioorg Med Chem Lett* 2003;13:841.
 88. Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. *Bioorg Med Chem* 2015;23:1828–40.
 89. Bejaoui M, Panatzi E, De Luca V, et al. Acetazolamide protects steatotic liver grafts against cold ischemia reperfusion injury. *J Pharmacol Exp Ther* 2015;355:191–8.
 90. Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. *J Enzyme Inhib Med Chem* 2016. [Epub ahead of print]. doi: 10.3109/14756366.2015.1113407.
 91. Sun MK, Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. *Trends Pharmacol Sci* 2002;23:83–92.
 92. Ilies M, Scozzafava A, Supuran CT. Carbonic anhydrase activators. In: Supuran CT, Scozzafava A, Conway J, eds. *Carbonic anhydrase – its inhibitors and activators*. Boca Raton, FL: CRC Press; 2004:317–52.
 93. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. *Arch Gerontol Geriatr* 1984;3:161–5.
 94. Temperini C, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: kinetic and X-ray crystallographic study for the interaction of d- and l-tryptophan with the mammalian isoforms I–XIV. *Bioorg Med Chem* 2008;16:8373–8.
 95. Temperini C, Scozzafava A, Puccetti L, Supuran CT. Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with l-histidine as a platform for the design of stronger activators. *Bioorg Med Chem Lett* 2005;15:5136–41.
 96. Temperini C, Innocenti A, Scozzafava A, et al. Carbonic anhydrase activators: l-adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII and XIV. *Bioorg Med Chem Lett* 2007;17:628–35.
 97. Temperini C, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with l- and d-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. *J Med Chem* 2006;49:3019–27.
 98. Nishimori I, Onishi S, Vullo D, et al. Carbonic anhydrase activators. The first activation study of the human secretory isoform VI. *Bioorg Med Chem* 2007;15:5351–7.

99. Abdo MR, Vullo D, Saada MC, et al. Carbonic anhydrase activators: activation of human isozymes I, II and IX with phenylsulfonylhydrazido L-histidine derivatives. *Bioorg Med Chem Lett* 2009;19:2440–3.
100. Scozzafava A, Supuran CT. Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. *J Med Chem* 2002;45:284–91.
101. Scozzafava A, Supuran CT. Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. *Bioorg Med Chem Lett* 2002;12:1177–80.
102. Ilies M, Banciu MD, Ilies MA, et al. Carbonic anhydrase activators: design of high affinity isozymes I, II and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties. *J Med Chem* 2002;45:504–10.
103. Supuran CT, Scozzafava A, Carbonic anhydrase activators as potential anti-Alzheimer's disease agents. In: Smith HJ, Simons C, Sewell RDE, eds. *Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies*. Boca Raton, Florida: CRC Press; 2007:265–88.
104. Clare BW, Supuran CT. Carbonic anhydrase activators. 3: structure-activity correlations for a series of isozyme II activators. *J Pharm Sci* 1994;83:768–73.
105. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971;246:2561–73.
106. Scozzafava A, Supuran CT. Carbonic anhydrase activators – Part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties. *Eur J Med Chem* 2000;35:31–9.